Why BGPT?
logo

Review papers with raw data transparency

Quickly verify claims by accessing the underlying experimental data and figures.







Press Enter ↡ to solve



    Fuel Your Discoveries




     Quick Answer


    Core finding
    Mode I phosphorylation of MAP1B is driven primarily by JNK (SP600125-sensitive) in the developing embryonic mouse cortex, while Cdk5 phosphorylates MAP1B mode I only when paired with p25 (not p35).
    Key skepticism: inhibitor off-targets and the use of COS7 overexpression require careful controls before treating β€œCdk5 does/doesn’t phosphorylate in vivo” as fully proven at the kinase-substrate level.



     Long Answer


    Paper review (science-first): MAP1B phosphorylation is differentially regulated by Cdk5/p35, Cdk5/p25, and JNK
    Target paper DOI: 10.1016/j.bbrc.2005.03.132
    What the study claims: mode I phosphorylated MAP1B is JNK-dependent in developing embryonic cortex, but can become Cdk5-dependent when Cdk5 is activated by p25 rather than p35, with functional consequences for microtubule dynamics and neuronal migration.
    Visualize first: quantified in vivo migration effect of MAP1B overexpression
    The paper reports EGFP layer distribution at P0 (5 days after in utero electroporation) showing reduced cortical plate signal when MAP1B is overexpressed vs control.
    Mechanistic logic diagram (evidence-weighted)
    In developing cortex: JNK inhibition decreases mode I MAP1B phosphorylation, whereas Cdk5 inhibition does not (and Cdk5 inhibition can still suppress migration via other substrates, e.g., FAK Ser732).

    In pathological context proxy: Cdk5/p25 (not p35) robustly increases mode I MAP1B phosphorylation in COS7 coexpression.
    Evidence trace: key experiments and what they actually establish
    1) Pharmacology in primary cortex cultures/slice cultures
    • Readout: SMI31 antibody detects mode I phosphorylated MAP1B (paper describes SMI31 recognition of mode I phosphorylated MAP1B).
    • Observation: SP600125 (JNK inhibitor) decreases SMI31-detected mode I MAP1B phosphorylation; roscovitine (Cdk5 inhibitor) does not under tested conditions.
    • Dissociation: roscovitine reduces FAK Ser732 phosphorylation and inhibits neuronal migration, implying that Cdk5 affects migration via other substrates even when mode I MAP1B phosphorylation is unchanged.
    2) p35 vs p25 complex specificity in a heterologous system
    • Model: COS7 cells (endogenous p35/p25 reportedly not detected by immunoblot), then Cdk5 coexpressed with p35 or p25.
    • Observation: Cdk5+p35 yields little increase in SMI31-detected mode I phosphorylated MAP1B; Cdk5+p25 yields strong mode I phosphorylation.
    • Implication: substrate specificity or accessibility of Cdk5 changes with p35β†’p25 conversion.
    3) Functional link: MAP1B overexpression perturbs cortical migration
    • Design: in utero electroporation with MAP1B expression vector and EGFP reporter; quantified layer distribution at P0.
    • Result: decreased fraction reaching cortical plate and evidence of intermediate-zone stalling.
    • Interpretation (within paper): proper microtubule dynamics regulation is required for normal migration, consistent with MAP1B/mode I-related microtubule regulation.
    Skeptical critique: what could mislead us?
    1) Pharmacology β‰  kinase-substrate identity. Roscovitine and SP600125 are inhibitors that can have off-target effects at the concentrations used, and the paper explicitly acknowledges that higher roscovitine may affect other molecules besides Cdk5. This weakens inference from β€œmode I MAP1B phosphorylation doesn’t change with roscovitine” to β€œCdk5 cannot phosphorylate MAP1B in vivo.”

    2) Readout is epitope-based. SMI31 detection of β€œmode I phosphorylation” is a monoclonal antibody readout. Without direct phosphosite mapping in the experiment, changes in signal reflect epitope phosphorylation states and may integrate multiple phosphorylation events.

    3) COS7 overexpression context. COS7 is a heterologous cell line: Cdk5 complexes and MAP1B may localize/aggregate differently than in cortical neurons, and endogenous upstream signaling may differ.
    What would most strengthen or refute the paper’s causal claims?
    • Direct phosphosite mapping of MAP1B β€œmode I” sites under each condition (e.g., JNK inhibition, Cdk5 inhibition, p35 vs p25 complexes) rather than epitope inference.
    • Kinase-dead controls or genetic perturbations (e.g., Cdk5 catalytic perturbation) that reduce off-target uncertainty compared to small-molecule inhibitors.
    • Neuron-native reconstitution experiments that match localization/complex stoichiometry more closely than COS7 coexpression.
    • Clarify whether the migration phenotype arises specifically from altered MAP1B mode I phosphorylation vs altered total MAP1B levels/dynamics (the paper demonstrates MAP1B overexpression affects migration, but does not directly show mode I phosphorylation state is the sufficient mediator of that phenotype).
    BGPT β€œmodel check” against adjacent MAP1B biology (context)
    MAP1B is widely studied as a microtubule-associated phosphoprotein whose phosphorylation state can influence microtubule interactions and neuronal morphogenesis, including growth cone/axon behaviors. For example, a MAP1B-focused review emphasizes developmental regulation and phosphorylation-dependent control of MAP1B functions and links to neurobiology and disease contexts.
    Bespoke BGPT actions


    Feedback:    

    Updated: March 25, 2026

     BGPT Paper Review


    Study Novelty

    70%

    The study extends prior work linking JNK to MAP1B mode I phosphorylation by directly contrasting Cdk5 activation-state regulators (p35 vs p25) and tying the differential phosphorylation to a neuronal migration phenotype. This is a meaningful mechanistic extension rather than entirely new MAP1B biology.


    Scientific Quality

    60%

    Moderate mechanistic support with multiple experimental contexts (primary culture, slice culture, COS7 coexpression, and in utero electroporation). Main quality limitations are reliance on inhibitor specificity and an epitope-based phosphorylation readout (SMI31) without direct site-level validation; plus heterologous COS7 overexpression for p25-dependent phosphorylation.


    Study Generality

    50%

    Findings are strongly tied to embryonic cortical neurons/migration and to the specific β€˜mode I’ MAP1B phosphorylation concept. The disease implication (p25 in pathogenic brains) is plausible within the paper’s framework but not directly tested with disease tissue in the provided text, so generality to other systems is limited.


    Study Usefulness

    70%

    Useful as a mechanistic hypothesis generator and framework: it provides testable predictions about how p35β†’p25 conversion could switch Cdk5 substrate phosphorylation outcomes versus JNK-driven regulation in development.


    Study Reproducibility

    60%

    Methods include standard culture systems, inhibitors, immunoblot ratios, and electroporation assays with reported replicates for some experiments. However, reproducibility may be constrained by reliance on specific antibodies/epitope detection (SMI31) and by incomplete quantitative reporting of some intermediate signaling data in the provided text excerpt.


    Explanatory Depth

    60%

    The paper offers a coherent regulatory model (JNK drives mode I phosphorylation in development; p25 enables Cdk5-mediated mode I phosphorylation in pathological conditions) and connects MAP1B regulation to migration and microtubule dynamics. Mechanistic depth is moderate because causal links rely on inhibitor effects and epitope readouts rather than direct phosphosite-level enzymology in the same neuronal context.


    🎁 Authors: Collect 105 Free Science Tokens (β‰ˆ $10.5 USD)

    Claim My Author Tokens

    Use for 26 days of free BGPT access (4 tokens = 1 day) or trade/sell (β‰ˆ $10.5 USD)

     Top Data Sources ExportMCP


     Analysis Wizard



    Extract the explicit numeric values (e.g., cortical plate EGFP fractions) and generate a publication-style plot of reported effect sizes, plus an error-bar summary table from 10.1016/j.bbrc.2005.03.132.



     Hypothesis Graveyard


    That Cdk5/p35 directly phosphorylates MAP1B mode I in the embryonic cortex but is masked by epitope detection dynamicsβ€”this is disfavored because the paper reports lack of suppression of SMI31-detected mode I phosphorylation with roscovitine at 100 ΞΌM, and it explicitly documents JNK inhibitor sensitivity.


    That COS7 results directly reflect the endogenous kinase-substrate mechanism in cortical neuronsβ€”this is uncertain because COS7 is a heterologous system and the phosphorylation readout may depend on expression levels/localization and epitope accessibility.

     Science Art


    Paper Review: MAP1B phosphorylation is differentially regulated by Cdk5/p35, Cdk5/p25, and JNK Science Art

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion








    Get Ahead With Science Insights

    Custom summaries of the latest cutting edge Science research. Every Friday. No Ads.


    My BGPT






     Trending